flutamide has been researched along with Polycystic Ovary Syndrome in 80 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine whether low-dose flutamide administration to normal-weight women with polycystic ovary syndrome (PCOS) reduces abdominal fat deposition, attenuates accelerated lipid accumulation in newly formed adipocytes derived from subcutaneous (SC) abdominal adipose stem cells (ASCs), and/or alters glucose-lipid metabolism." | 9.69 | Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome. ( Abbott, DH; Chazenbalk, GD; Dumesic, DA; Grogan, TR; Lu, G; Naik, R; Winnett, C, 2023) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 9.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| "To assess the effectiveness of flutamide in the treatment of hirsutism, used as monotherapy or combined with oral contraceptives (OC)." | 9.11 | [Effectiveness of flutamide alone or combined with oral contraceptives in the treatment of hirsutism in women]. ( Aravena, L; Devoto, E, 2004) |
| "To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH)." | 9.11 | Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. ( Inal, MM; Taner, CE; Yildirim, Y, 2005) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)." | 9.11 | Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004) |
| "To evaluate whether, by blocking androgen action, flutamide can decrease and normalize vascular resistance in the uterine artery in patients with polycystic ovary syndrome (PCOS)." | 9.10 | The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2002) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 9.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "To evaluate the serum leptin levels and the effects of flutamide treatment on the leptin levels in women with polycystic ovary syndrome (PCOS)." | 9.10 | Leptin levels increase during flutamide therapy in women with polycystic ovary syndrome. ( Aral, Y; Culha, C; Demirbas, B; Guler, S; Karakurt, F; Sahin, I; Serter, R; Taskapan, C, 2003) |
| "The objective of this prospective randomized study was to evaluate and compare the hormonal and clinical effects of long-acting gonadotropin-releasing hormone (GnRH) agonist and a combination of GnRH agonist with combined oral contraceptive (COC) or flutamide in women with polycystic ovary syndrome (PCOS)." | 9.09 | Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism. ( Caruso, A; De Leo, V; Fulghesu, AM; la Marca, A; Morgante, G; Pasqui, L; Talluri, B; Torricelli, M, 2000) |
| "To compare the long-term (1 year) effects of flutamide (250 mg/d) and finasteride (5 mg/d) for the treatment of hirsutism in women." | 9.09 | A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. ( Bayram, F; Güven, M; Müderris, II, 2000) |
| "To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months." | 9.09 | Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. ( Caputo, M; Castello, R; Misciali, C; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F; Tosti, A, 2000) |
| "Both drugs are effective in the treatment of hirsutism but flutamide is more effective than finasteride." | 9.09 | Comparison of finasteride versus flutamide in the treatment of hirsutism. ( Bugari, G; Falsetti, L; Gambera, A; Iacobello, C; Legrenzi, L, 1999) |
| "To investigate insulin metabolism and its modifications induced by the administration of flutamide, a specific antiandrogen compound, in women with idiopathic hirsutism (IH) and in nonobese women with polycystic ovary syndrome (PCOS)." | 9.09 | Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. ( Ajossa, S; Cagnacci, A; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 1999) |
| "Forty-four hirsute patients with polycystic ovary syndrome were randomly treated with finasteride (5 mg daily) or flutamide (250 mg twice daily) for 6 consecutive months." | 9.08 | Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. ( De Fusco, D; Eleftheriou, G; Falsetti, L; Rosina, B, 1997) |
| "The aim of this work was to evaluate the efficacy of two new antiandrogen drugs, finasteride and flutamide, in 80 hirsute patients: 44 with Polycystic Ovary Syndrome (PCOS) and 36 with Idiopathic Hirsutism (IH)." | 9.08 | [Finasteride and flutamide in the treatment of hirsutism]. ( De Fusco, D; Falsetti, L; Rosina, B, 1997) |
| "Flutamide, associated with low dosage OC, favorably influence the hirsutism in PCOD women who are unresponsive to OC treatment alone." | 9.07 | Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients. ( Aglianò, A; Cianci, A; Ciotta, L; Marletta, E; Palumbo, G; Pisana, L, 1994) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 7.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| "The long-term effects and tolerability of flutamide (Flu) on the menstrual cycle and the ovulatory function of hyperandrogenic women with or without polycystic ovary syndrome (PCOS) were investigated." | 7.79 | Ovulatory effects of flutamide in the polycystic ovary syndrome. ( Battaglia, C; Fabbri, R; Paradisi, R; Venturoli, S, 2013) |
| " PCOS induced rats with ovulation blockade, persistent estrus and polycystic ovary resumed estrous cycle in 3-4 days post noscapine administration (120 mg/kg bwt/day)." | 7.75 | Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome. ( Priyadarshani, A, 2009) |
| "The authors hope that flutamide could enter in the list of medicines normally used to treat the beauty flaws of policistic acne and to restore a hormonal order associated to an effective contraception." | 7.74 | [Low-dose flutamide in the treatment of hyperandrogenism in adolescents]. ( Borrielli, I; Dinatale, A; Dugo, C; Dugo, N; Fattori, A; Mastroeni, MT; Pizzo, A, 2008) |
| "The authors evaluate the effects of 2 months of treatment with 250 mg flutamide daily on adrenal steroidogenesis (ACTH test) and metabolic parameters (lipids, insulin resistance) in 12 PCOS women aged 33." | 7.72 | Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. ( Dvoráková, K; Hill, M; Stanická, S; Stárka, L; Vondra, K; Vrbíková, J, 2004) |
| "The aim of our study was to evaluate the clinical efficacy of flutamide (Flu), when used alone, on the course of hirsutism and to assess its effect on hormonal secretion." | 7.69 | The use of flutamide in the management of hirsutism. ( Badaracco, B; Bernasconi, D; Del Monte, P; Marugo, M; Meozzi, M; Primarolo, P; Zino, V, 1994) |
| "To explore the clinical usefulness of the antiandrogen flutamide in the treatment modality for hirsutism in women." | 7.68 | Treatment of hirsutism in women with flutamide. ( Kirschner, MA; Luthold, WW; Marcondes, JA; Minnani, SL; Samojlik, E; Wajchenberg, BL, 1992) |
| "In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS." | 6.71 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. ( Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C, 2004) |
| "Insulin sensitivity was assessed by homeostasis model assessment (HOMA)." | 6.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "Flutamide is a nonsteroid antiandrogen that has been found effective in hirsute patients, although its mechanism of action is unclear." | 6.69 | Hormonal effects of flutamide in young women with polycystic ovary syndrome. ( D'Antona, D; De Leo, V; la Marca, A; Lanzetta, D; Morgante, G, 1998) |
| "To examine whether low-dose flutamide administration to normal-weight women with polycystic ovary syndrome (PCOS) reduces abdominal fat deposition, attenuates accelerated lipid accumulation in newly formed adipocytes derived from subcutaneous (SC) abdominal adipose stem cells (ASCs), and/or alters glucose-lipid metabolism." | 5.69 | Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome. ( Abbott, DH; Chazenbalk, GD; Dumesic, DA; Grogan, TR; Lu, G; Naik, R; Winnett, C, 2023) |
| "Flutamide treatment can efficiently ameliorate the hyperandrogenemia-induced the disorders in aspects of decidualization, angiogenesis and uNK cells, which further improve the poor endometrial receptivity in PCOS patients." | 5.51 | Flutamide ameliorates uterine decidualization and angiogenesis in the mouse hyperandrogenemia model during mid-pregnancy. ( Gong, H; Kuang, H; Li, Y; Ling, Y; Liu, H; Qiao, B; Wu, W; Xu, J; Yang, B; Yu, D, 2019) |
| "Hirsutism was defined by modified Ferriman-Gallwey score (FGS)." | 5.32 | Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination. ( Bahceci, M; Bahceci, S; Bilge, M; Tuzcu, A; Tuzcu, S, 2004) |
| "Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0." | 5.30 | The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Duleba, AJ; Mitrakou, A; Raptis, S; Tolis, G, 1998) |
| "Hirsutism is a common symptom of women affected by polycystic ovary syndrome (PCOS)." | 5.29 | Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. ( Angelini, F; Barletta, D; Gargani, M; Genazzani, AD; Genazzani, AR; Lippi, F; Luisi, M; Monzani, F; Pucci, E, 1995) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 5.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "To assess the effectiveness of flutamide in the treatment of hirsutism, used as monotherapy or combined with oral contraceptives (OC)." | 5.11 | [Effectiveness of flutamide alone or combined with oral contraceptives in the treatment of hirsutism in women]. ( Aravena, L; Devoto, E, 2004) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| "To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH)." | 5.11 | Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. ( Inal, MM; Taner, CE; Yildirim, Y, 2005) |
| "Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)." | 5.11 | Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "To evaluate whether, by blocking androgen action, flutamide can decrease and normalize vascular resistance in the uterine artery in patients with polycystic ovary syndrome (PCOS)." | 5.10 | The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2002) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 5.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "To evaluate the serum leptin levels and the effects of flutamide treatment on the leptin levels in women with polycystic ovary syndrome (PCOS)." | 5.10 | Leptin levels increase during flutamide therapy in women with polycystic ovary syndrome. ( Aral, Y; Culha, C; Demirbas, B; Guler, S; Karakurt, F; Sahin, I; Serter, R; Taskapan, C, 2003) |
| "Both drugs are effective in the treatment of hirsutism but flutamide is more effective than finasteride." | 5.09 | Comparison of finasteride versus flutamide in the treatment of hirsutism. ( Bugari, G; Falsetti, L; Gambera, A; Iacobello, C; Legrenzi, L, 1999) |
| "The objective of this prospective randomized study was to evaluate and compare the hormonal and clinical effects of long-acting gonadotropin-releasing hormone (GnRH) agonist and a combination of GnRH agonist with combined oral contraceptive (COC) or flutamide in women with polycystic ovary syndrome (PCOS)." | 5.09 | Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism. ( Caruso, A; De Leo, V; Fulghesu, AM; la Marca, A; Morgante, G; Pasqui, L; Talluri, B; Torricelli, M, 2000) |
| "To compare the long-term (1 year) effects of flutamide (250 mg/d) and finasteride (5 mg/d) for the treatment of hirsutism in women." | 5.09 | A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. ( Bayram, F; Güven, M; Müderris, II, 2000) |
| "To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months." | 5.09 | Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. ( Caputo, M; Castello, R; Misciali, C; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F; Tosti, A, 2000) |
| "To investigate insulin metabolism and its modifications induced by the administration of flutamide, a specific antiandrogen compound, in women with idiopathic hirsutism (IH) and in nonobese women with polycystic ovary syndrome (PCOS)." | 5.09 | Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. ( Ajossa, S; Cagnacci, A; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 1999) |
| "Forty-four hirsute patients with polycystic ovary syndrome were randomly treated with finasteride (5 mg daily) or flutamide (250 mg twice daily) for 6 consecutive months." | 5.08 | Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. ( De Fusco, D; Eleftheriou, G; Falsetti, L; Rosina, B, 1997) |
| "The aim of this work was to evaluate the efficacy of two new antiandrogen drugs, finasteride and flutamide, in 80 hirsute patients: 44 with Polycystic Ovary Syndrome (PCOS) and 36 with Idiopathic Hirsutism (IH)." | 5.08 | [Finasteride and flutamide in the treatment of hirsutism]. ( De Fusco, D; Falsetti, L; Rosina, B, 1997) |
| " To distinguish the mechanisms of this association, we determined the interactions of PCO with obesity and the influence of ameliorating direct androgenic actions via short-term treatment with the antiandrogen flutamide." | 5.08 | Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Georgiadou, E; Hennes, MM; Hoffmann, RG; Kaklas, N; Kissebah, AH; Mitrakou, A; Platanissiotis, D; Raptis, S; Spina, J, 1995) |
| "Flutamide, associated with low dosage OC, favorably influence the hirsutism in PCOD women who are unresponsive to OC treatment alone." | 5.07 | Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients. ( Aglianò, A; Cianci, A; Ciotta, L; Marletta, E; Palumbo, G; Pisana, L, 1994) |
| " Indirect evidence from populations without PCOS demonstrated no increased risk of lactic acidosis with metformin, only case reports of liver toxicity with flutamide (no comparative evidence), and increased relative risk difference of venous thromboembolism with oral contraceptive pills but very low absolute risk." | 4.89 | Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. ( Domecq, JP; Ehrmann, D; Erwin, PJ; Montori, VM; Mullan, RJ; Murad, MH; Prutsky, G; Sundaresh, V; Wang, AT; Welt, C, 2013) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: finasteride, flutamide, metformin, spironolactone, cyproterone acetate-ethinylestradiol (co-cyprindiol), interventions to achieve weight loss, ketoconazole, and mechanical hair removal." | 4.85 | PCOS. ( Cahill, D, 2009) |
| "Fifty NMRI mice (7-8 weeks old) were randomly divided into five groups, including non-PCOS, PCOS and PCOS groups treated with clomiphene citrate (18 mg/kg body weight for 2 days), metformin (50 mg/100 g body weight for 30 days) and flutamide (10 mg/kg body weight injection for 15 days)." | 4.12 | Metformin, clomiphene citrate and flutamide effects on oocyte ultrastructure status and quality in PCOS mouse model. ( Esmaeilnezhad, S; Ghasemian, F, 2022) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 3.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| " This study tested whether 1) in utero cotreatment of prenatally T-treated sheep with androgen antagonist (flutamide) or insulin sensitizer (rosiglitazone) prevents juvenile insulin resistance and adult changes in adipocyte size; and 2) visceral adiposity and insulin sensitivity are both unaltered during early adulthood, confirming the predicted developmental trajectory in this animal model." | 3.83 | Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep. ( Beckett, E; Cardoso, RC; Chazenbalk, G; Dumesic, D; Keller, E; Madrigal, V; Moeller, J; Padmanabhan, V; Pease, A; Veiga-Lopez, A, 2016) |
| "The long-term effects and tolerability of flutamide (Flu) on the menstrual cycle and the ovulatory function of hyperandrogenic women with or without polycystic ovary syndrome (PCOS) were investigated." | 3.79 | Ovulatory effects of flutamide in the polycystic ovary syndrome. ( Battaglia, C; Fabbri, R; Paradisi, R; Venturoli, S, 2013) |
| " PCOS induced rats with ovulation blockade, persistent estrus and polycystic ovary resumed estrous cycle in 3-4 days post noscapine administration (120 mg/kg bwt/day)." | 3.75 | Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome. ( Priyadarshani, A, 2009) |
| "The authors hope that flutamide could enter in the list of medicines normally used to treat the beauty flaws of policistic acne and to restore a hormonal order associated to an effective contraception." | 3.74 | [Low-dose flutamide in the treatment of hyperandrogenism in adolescents]. ( Borrielli, I; Dinatale, A; Dugo, C; Dugo, N; Fattori, A; Mastroeni, MT; Pizzo, A, 2008) |
| "The authors evaluate the effects of 2 months of treatment with 250 mg flutamide daily on adrenal steroidogenesis (ACTH test) and metabolic parameters (lipids, insulin resistance) in 12 PCOS women aged 33." | 3.72 | Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. ( Dvoráková, K; Hill, M; Stanická, S; Stárka, L; Vondra, K; Vrbíková, J, 2004) |
| "The aim of our study was to evaluate the clinical efficacy of flutamide (Flu), when used alone, on the course of hirsutism and to assess its effect on hormonal secretion." | 3.69 | The use of flutamide in the management of hirsutism. ( Badaracco, B; Bernasconi, D; Del Monte, P; Marugo, M; Meozzi, M; Primarolo, P; Zino, V, 1994) |
| "To explore the clinical usefulness of the antiandrogen flutamide in the treatment modality for hirsutism in women." | 3.68 | Treatment of hirsutism in women with flutamide. ( Kirschner, MA; Luthold, WW; Marcondes, JA; Minnani, SL; Samojlik, E; Wajchenberg, BL, 1992) |
| "In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS." | 2.71 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. ( Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C, 2004) |
| "Insulin sensitivity was assessed by homeostasis model assessment (HOMA)." | 2.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "Flutamide is a nonsteroid antiandrogen that has been found effective in hirsute patients, although its mechanism of action is unclear." | 2.69 | Hormonal effects of flutamide in young women with polycystic ovary syndrome. ( D'Antona, D; De Leo, V; la Marca, A; Lanzetta, D; Morgante, G, 1998) |
| "Hirsutism is a common disorder with a major impact on quality of life." | 2.53 | Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments. ( Fedorowicz, Z; van Zuuren, EJ, 2016) |
| " The secondary outcome measures include acne scores, prevalence of dysglycaemia, BMI, lipid profile, total testosterone level, and adverse events." | 2.52 | The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Flórez, ID; Neupane, B; Thabane, L, 2015) |
| "Acne vulgaris is a common reason why adult women present to dermatologists and can be a clinical challenge to treat." | 2.48 | Acne in the adult female patient: a practical approach. ( Kamangar, F; Shinkai, K, 2012) |
| "While the treatment of hyperandrogenism makes use of different drugs already studied, the debate about the use of insulin sensitizing drugs is still open." | 2.42 | Which treatment options should be used in adolescents with polycystic ovary syndrome? ( Barini, A; Di Sebastiano, F; Fulghesu, AM; Lanzone, A; Rossodivita, A; Sagnella, F; Villa, P, 2004) |
| "Although hirsutism and androgenetic alopecia are cosmetic problems, they can be psychologically devastating for women." | 2.40 | Antiandrogen treatment of polycystic ovary syndrome. ( Rittmaster, RS, 1999) |
| "Flutamide treatment can efficiently ameliorate the hyperandrogenemia-induced the disorders in aspects of decidualization, angiogenesis and uNK cells, which further improve the poor endometrial receptivity in PCOS patients." | 1.51 | Flutamide ameliorates uterine decidualization and angiogenesis in the mouse hyperandrogenemia model during mid-pregnancy. ( Gong, H; Kuang, H; Li, Y; Ling, Y; Liu, H; Qiao, B; Wu, W; Xu, J; Yang, B; Yu, D, 2019) |
| "Pretreatment with flutamide, as well as knockdown of androgen receptor, decreased testosterone-induced DR5 and CHOP expression, as well as apoptosis." | 1.51 | Endoplasmic Reticulum Stress Activated by Androgen Enhances Apoptosis of Granulosa Cells via Induction of Death Receptor 5 in PCOS. ( Azhary, JMK; Fujii, T; Harada, M; Hirata, T; Hirota, Y; Koga, K; Koike, H; Kunitomi, C; Nose, E; Osuga, Y; Takahashi, N; Wada-Hiraike, O, 2019) |
| "Flutamide treatment in LET females reversed elevated T levels and restored ovarian expression of Cyp17a1 (critical for androgen synthesis) to normal levels." | 1.48 | Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS. ( Malik, S; Mellon, PL; Ryan, GE, 2018) |
| "Hirsutism affects 5-8% of the whole female population." | 1.39 | Hirsutism - from diagnosis to use of antiandrogens. ( Karaca, Z; Kelestimur, F; Unluhizarci, K, 2013) |
| "Flutamide is a pure non-steroidal anti-androgen that may be hepatotoxic, when given in high-dose (750 mg/d)." | 1.33 | Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. ( de Zegher, F; Ferrer, A; Ibáñez, L; Jaramillo, A, 2005) |
| "Hirsutism was defined by modified Ferriman-Gallwey score (FGS)." | 1.32 | Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination. ( Bahceci, M; Bahceci, S; Bilge, M; Tuzcu, A; Tuzcu, S, 2004) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0." | 1.30 | The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Duleba, AJ; Mitrakou, A; Raptis, S; Tolis, G, 1998) |
| "Flutamide is a non-steroid antiandrogen that specifically blocks the androgen receptor." | 1.30 | Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF). ( Cariello, PL; D'Antona, D; De Leo, V; la Marca, A; Lanzetta, D; Morgante, G, 1998) |
| "Hirsutism is a common symptom of women affected by polycystic ovary syndrome (PCOS)." | 1.29 | Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. ( Angelini, F; Barletta, D; Gargani, M; Genazzani, AD; Genazzani, AR; Lippi, F; Luisi, M; Monzani, F; Pucci, E, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (20.00) | 18.2507 |
| 2000's | 34 (42.50) | 29.6817 |
| 2010's | 23 (28.75) | 24.3611 |
| 2020's | 7 (8.75) | 2.80 |
| Authors | Studies |
|---|---|
| Abdalla, MA | 1 |
| Shah, N | 1 |
| Deshmukh, H | 1 |
| Sahebkar, A | 1 |
| Östlundh, L | 1 |
| Al-Rifai, RH | 1 |
| Atkin, SL | 1 |
| Sathyapalan, T | 1 |
| Ghasemian, F | 1 |
| Esmaeilnezhad, S | 1 |
| Zolton, JR | 1 |
| Dumesic, DA | 3 |
| Winnett, C | 3 |
| Lu, G | 3 |
| Grogan, TR | 3 |
| Abbott, DH | 3 |
| Naik, R | 3 |
| Chazenbalk, GD | 3 |
| Zhao, XD | 1 |
| Li, ZH | 1 |
| Hu, JW | 1 |
| Chen, YL | 1 |
| Xu, G | 1 |
| Gisela S, B | 1 |
| M Virginia, A | 1 |
| Gabriela A, A | 1 |
| M Virginia, T | 1 |
| Enrique H, L | 1 |
| Laura, K | 1 |
| Véronica L, B | 1 |
| Landers, RSM | 1 |
| Padmanabhan, V | 4 |
| Cardoso, RC | 3 |
| Ryan, GE | 1 |
| Malik, S | 1 |
| Mellon, PL | 1 |
| Lu, C | 1 |
| Hutchens, EG | 1 |
| Farhy, LS | 1 |
| Bonner, HG | 1 |
| Suratt, PM | 1 |
| McCartney, CR | 1 |
| Kupreeva, M | 1 |
| Diane, A | 1 |
| Lehner, R | 1 |
| Watts, R | 1 |
| Ghosh, M | 1 |
| Proctor, S | 1 |
| Vine, D | 1 |
| Azarchi, S | 1 |
| Bienenfeld, A | 1 |
| Lo Sicco, K | 1 |
| Marchbein, S | 1 |
| Shapiro, J | 1 |
| Nagler, AR | 1 |
| Azhary, JMK | 1 |
| Harada, M | 1 |
| Takahashi, N | 1 |
| Nose, E | 1 |
| Kunitomi, C | 1 |
| Koike, H | 1 |
| Hirata, T | 1 |
| Hirota, Y | 1 |
| Koga, K | 1 |
| Wada-Hiraike, O | 1 |
| Fujii, T | 1 |
| Osuga, Y | 1 |
| Gong, H | 1 |
| Wu, W | 1 |
| Xu, J | 1 |
| Yu, D | 1 |
| Qiao, B | 1 |
| Liu, H | 1 |
| Yang, B | 1 |
| Li, Y | 1 |
| Ling, Y | 1 |
| Kuang, H | 1 |
| Boztosun, A | 1 |
| Açmaz, G | 1 |
| Ozturk, A | 1 |
| Müderris, II | 2 |
| Unluhizarci, K | 1 |
| Karaca, Z | 1 |
| Kelestimur, F | 1 |
| Domecq, JP | 1 |
| Prutsky, G | 1 |
| Mullan, RJ | 1 |
| Sundaresh, V | 1 |
| Wang, AT | 1 |
| Erwin, PJ | 1 |
| Welt, C | 1 |
| Ehrmann, D | 1 |
| Montori, VM | 1 |
| Murad, MH | 1 |
| Buzney, E | 1 |
| Sheu, J | 1 |
| Buzney, C | 1 |
| Reynolds, RV | 1 |
| Veiga-Lopez, A | 2 |
| Herkimer, C | 1 |
| Abi Salloum, B | 1 |
| Moeller, J | 3 |
| Beckett, E | 2 |
| Sreedharan, R | 1 |
| Yang, F | 1 |
| Ruan, YC | 1 |
| Yang, YJ | 1 |
| Wang, K | 1 |
| Liang, SS | 1 |
| Han, YB | 1 |
| Teng, XM | 1 |
| Yang, JZ | 1 |
| Hurliman, A | 1 |
| Keller Brown, J | 1 |
| Maille, N | 1 |
| Mandala, M | 1 |
| Casson, P | 1 |
| Osol, G | 1 |
| Al Khalifah, RA | 1 |
| Flórez, ID | 1 |
| Dennis, B | 1 |
| Neupane, B | 1 |
| Thabane, L | 1 |
| Bassilious, E | 1 |
| Pease, A | 1 |
| Keller, E | 1 |
| Madrigal, V | 1 |
| Chazenbalk, G | 1 |
| Dumesic, D | 1 |
| Li, X | 1 |
| Pishdari, B | 1 |
| Cui, P | 1 |
| Hu, M | 1 |
| Yang, HP | 1 |
| Guo, YR | 1 |
| Jiang, HY | 1 |
| Feng, Y | 1 |
| Billig, H | 1 |
| Shao, R | 1 |
| van Zuuren, EJ | 1 |
| Fedorowicz, Z | 1 |
| Burns, A | 1 |
| Skinner, DC | 1 |
| Pizzo, A | 1 |
| Borrielli, I | 1 |
| Mastroeni, MT | 1 |
| Fattori, A | 1 |
| Dugo, C | 1 |
| Dugo, N | 1 |
| Dinatale, A | 1 |
| Cahill, D | 1 |
| Priyadarshani, A | 1 |
| Reznikov, OH | 1 |
| Borys, OM | 1 |
| Nosenko, ND | 1 |
| Sinitsyn, PV | 1 |
| Tarasenko, LV | 1 |
| Poliakova, LI | 1 |
| Ibáñez, L | 11 |
| López-Bermejo, A | 1 |
| Díaz, M | 3 |
| Enríquez, G | 1 |
| Del Río, L | 1 |
| De Zegher, F | 9 |
| Lázaro, I | 1 |
| Cabré, A | 1 |
| Masana, L | 1 |
| Vinaixa, M | 1 |
| Rodriguez, MA | 1 |
| Samino, S | 1 |
| Beltran, A | 1 |
| Mallol, R | 1 |
| Bladé, C | 1 |
| Correig, X | 1 |
| Yanes, O | 1 |
| Kamangar, F | 1 |
| Shinkai, K | 1 |
| Paradisi, R | 1 |
| Fabbri, R | 1 |
| Battaglia, C | 1 |
| Venturoli, S | 1 |
| Ong, K | 1 |
| Ferrer, A | 2 |
| Amin, R | 1 |
| Dunger, D | 1 |
| Gambineri, A | 3 |
| Pagotto, U | 3 |
| Tschöp, M | 1 |
| Vicennati, V | 1 |
| Manicardi, E | 1 |
| Carcello, A | 1 |
| Cacciari, M | 3 |
| De Iasio, R | 1 |
| Pasquali, R | 3 |
| Sahin, I | 2 |
| Serter, R | 2 |
| Karakurt, F | 2 |
| Demirbas, B | 2 |
| Guler, S | 1 |
| Culha, C | 2 |
| Taskapan, C | 2 |
| Aral, Y | 2 |
| Pelusi, C | 1 |
| Genghini, S | 1 |
| Morselli-Labate, AM | 2 |
| Ajossa, S | 3 |
| Guerriero, S | 3 |
| Paoletti, AM | 3 |
| Orrù, M | 3 |
| Melis, GB | 3 |
| Vrbíková, J | 1 |
| Hill, M | 1 |
| Dvoráková, K | 1 |
| Stanická, S | 1 |
| Vondra, K | 1 |
| Stárka, L | 1 |
| Bahceci, M | 1 |
| Bilge, M | 1 |
| Tuzcu, A | 1 |
| Tuzcu, S | 1 |
| Bahceci, S | 1 |
| Villa, P | 1 |
| Di Sebastiano, F | 1 |
| Rossodivita, A | 1 |
| Sagnella, F | 1 |
| Barini, A | 1 |
| Fulghesu, AM | 2 |
| Lanzone, A | 1 |
| Valls, C | 1 |
| Cabré, S | 1 |
| Devoto, E | 1 |
| Aravena, L | 1 |
| Kosar, F | 1 |
| Jaramillo, A | 1 |
| Al-Inany, H | 2 |
| Inal, MM | 1 |
| Yildirim, Y | 1 |
| Taner, CE | 1 |
| Moghetti, P | 3 |
| Mehta, RV | 1 |
| Malcom, PJ | 1 |
| Chang, RJ | 1 |
| Patton, L | 1 |
| Vaccina, A | 1 |
| Cavazza, C | 1 |
| Legro, RS | 1 |
| Corbould, A | 1 |
| Diamanti-Kandarakis, E | 3 |
| Mitrakou, A | 2 |
| Hennes, MM | 1 |
| Platanissiotis, D | 1 |
| Kaklas, N | 1 |
| Spina, J | 1 |
| Georgiadou, E | 1 |
| Hoffmann, RG | 1 |
| Kissebah, AH | 1 |
| Raptis, S | 2 |
| Ciotta, L | 1 |
| Cianci, A | 1 |
| Marletta, E | 1 |
| Pisana, L | 1 |
| Aglianò, A | 1 |
| Palumbo, G | 1 |
| Marugo, M | 1 |
| Bernasconi, D | 1 |
| Meozzi, M | 1 |
| Del Monte, P | 1 |
| Zino, V | 1 |
| Primarolo, P | 1 |
| Badaracco, B | 1 |
| Pucci, E | 1 |
| Genazzani, AD | 1 |
| Monzani, F | 1 |
| Lippi, F | 1 |
| Angelini, F | 1 |
| Gargani, M | 1 |
| Barletta, D | 1 |
| Luisi, M | 1 |
| Genazzani, AR | 1 |
| Ruiz, A | 1 |
| Aguilar, R | 1 |
| Tébar, AM | 1 |
| Gaytán, F | 1 |
| Sánchez-Criado, JE | 1 |
| Falsetti, L | 3 |
| De Fusco, D | 2 |
| Eleftheriou, G | 1 |
| Rosina, B | 2 |
| De Leo, V | 3 |
| Lanzetta, D | 2 |
| D'Antona, D | 2 |
| la Marca, A | 3 |
| Morgante, G | 3 |
| Tolis, G | 1 |
| Duleba, AJ | 1 |
| Cariello, PL | 1 |
| Castello, R | 2 |
| Zamberlan, N | 1 |
| Rossini, M | 1 |
| Gatti, D | 1 |
| Negri, C | 2 |
| Tosi, F | 2 |
| Muggeo, M | 2 |
| Adami, S | 1 |
| Rittmaster, RS | 1 |
| Cagnacci, A | 1 |
| Gambera, A | 1 |
| Legrenzi, L | 1 |
| Iacobello, C | 1 |
| Bugari, G | 1 |
| Tosti, A | 1 |
| Misciali, C | 1 |
| Perrone, F | 1 |
| Caputo, M | 1 |
| Bayram, F | 1 |
| Güven, M | 1 |
| Eagleson, CA | 1 |
| Gingrich, MB | 1 |
| Pastor, CL | 1 |
| Arora, TK | 1 |
| Burt, CM | 1 |
| Evans, WS | 1 |
| Marshall, JC | 1 |
| Pasqui, L | 1 |
| Talluri, B | 1 |
| Torricelli, M | 1 |
| Caruso, A | 1 |
| Marcondes, JA | 1 |
| Minnani, SL | 1 |
| Luthold, WW | 1 |
| Wajchenberg, BL | 1 |
| Samojlik, E | 1 |
| Kirschner, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women[NCT01889199] | Phase 2 | 45 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Topical Silymarin Cream Versus Salicylic Acid Peeling in Treatment of Acne Vulgaris: Split Face Study[NCT04490967] | Phase 4 | 30 participants (Anticipated) | Interventional | 2021-04-30 | Not yet recruiting | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Metabolic Syndrome in PCOS: Precursors and Interventions[NCT00442689] | 97 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Theca Cell Function in Women With Polycystic Ovary Syndrome[NCT00747617] | Phase 3 | 25 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)[NCT05979389] | Phase 1 | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months
| Intervention | min^-1 (Mean) |
|---|---|
| Oral Contraceptive - 1 | 1653 |
| Flutamide - 2 | 194 |
| Placebo - 3 | -184 |
Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months
| Intervention | percentage of body mass (Mean) |
|---|---|
| Oral Contraceptive - 1 | 0.4 |
| Flutamide - 2 | -1.9 |
| Placebo - 3 | -1.9 |
Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | 6 |
| Flutamide - 2 | -5 |
| Placebo - 3 | -2 |
Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | -6 |
| Flutamide - 2 | -9 |
| Placebo - 3 | -7 |
Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months
| Intervention | L/min (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.5 |
| Flutamide - 2 | -1.6 |
| Placebo - 3 | 1.1 |
Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months
| Intervention | Kcal/day (Mean) |
|---|---|
| Oral Contraceptive - 1 | 7 |
| Flutamide - 2 | -79 |
| Placebo - 3 | -88 |
Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months
| Intervention | L (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.1 |
| Flutamide - 2 | -0.1 |
| Placebo - 3 | 0.1 |
Mean serum testosterone levels before and after hCG injection. Serum testosterone levels before (-0.5 and 0 hrs) were averaged to achieve a single value (NCT00747617)
Timeframe: -0.5, 0, 24 hrs
| Intervention | ng/ml (Mean) |
|---|---|
| PCOS | 0.6 |
| Normal | 0.3 |
Assess serum 17OHP levels following each dose of hCG adminstration in PCOS and normal subjects (NCT00747617)
Timeframe: 24 hrs post dose
| Intervention | ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| 17OHP post 10 micrograms | 17OHP level post 1 micrograms | 17OHP level post 25 micrograms | 17OHP level post 100 micrograms | 17OHP level post 250 micrograms | |
| Normal | 1.2 | 1.0 | 1.7 | 2.2 | 2.1 |
| PCOS | 2.0 | 1.1 | 2.7 | 3.3 | 4.0 |
13 reviews available for flutamide and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.
Topics: Androgens; Dexamethasone; Female; Flutamide; Humans; Hyperandrogenism; Metformin; Polycystic Ovary S | 2023 |
Androgens in women: Hormone-modulating therapies for skin disease.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Adrenal Hyperplasia, Congenital; Alopecia; Androgen Ant | 2019 |
Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Androgen Antagonists; Contraceptives, Oral; Evidence-Based Medicine; Female; Flutamide; Humans; Hypo | 2013 |
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C | 2014 |
The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Diet; Drug Therapy, Combination; Exercise; F | 2015 |
Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Androgen Antagonists; Body Mass Index; Contraceptives, Ora | 2016 |
PCOS.
Topics: Diabetes Mellitus, Type 2; Flutamide; Hair Removal; Hirsutism; Humans; Metformin; Polycystic Ovary S | 2009 |
Acne in the adult female patient: a practical approach.
Topics: Acne Vulgaris; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral, Hormonal; Dermatologic | 2012 |
Which treatment options should be used in adolescents with polycystic ovary syndrome?
Topics: Adolescent; Adolescent Health Services; Adult; Androgen Antagonists; Estrogens; Female; Flutamide; H | 2004 |
Polycystic ovary syndrome.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Fin | 2004 |
Polycystic ovary syndrome.
Topics: Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Finasteride; Flutamide; H | 2005 |
How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?
Topics: Androgen Antagonists; Cyproterone Acetate; Female; Finasteride; Flutamide; Humans; Polycystic Ovary | 1998 |
Antiandrogen treatment of polycystic ovary syndrome.
Topics: Alopecia; Androgen Antagonists; Androgens; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirs | 1999 |
31 trials available for flutamide and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Topics: Female; Flutamide; Glucose; Humans; Lipids; Lipoproteins; Lipoproteins, LDL; Polycystic Ovary Syndro | 2023 |
Influence of Sleep Stage on LH Pulse Initiation in the Normal Late Follicular Phase and in Polycystic Ovary Syndrome.
Topics: Adult; Androgen Antagonists; Cross-Over Studies; Estradiol; Female; Flutamide; Follicular Phase; Hum | 2018 |
Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.
Topics: Adolescent; Alanine Transaminase; Androgens; Androstenes; Aspartate Aminotransferases; Blood Glucose | 2010 |
Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Topics: Adolescent; Androgen Antagonists; Biomarkers; Body Mass Index; Child; Contraceptives, Oral, Combined | 2011 |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.
Topics: Abdominal Fat; Biomarkers; Carotid Intima-Media Thickness; Chromatography, Gas; Chromatography, Liqu | 2011 |
Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cohort Studies; Contraceptives, Oral; Dose-Response Relationship, Drug; | 2003 |
Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Topics: Adipose Tissue; Androgen Antagonists; Child; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2003 |
Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Androstenedione; Blood Glucose; Body Composition; Body Weight; Female; | 2003 |
Leptin levels increase during flutamide therapy in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Anthropometry; Area Under Curve; Blood Glucose; Case-Contro | 2003 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Topics: Adiponectin; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Androstenes; Drug Therapy, Com | 2004 |
Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Therapy | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Topics: Adiponectin; Adolescent; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol | 2004 |
[Effectiveness of flutamide alone or combined with oral contraceptives in the treatment of hirsutism in women].
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Biomarkers; Cohort Studies; Contraceptives, Oral | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Topics: Adolescent; Adult; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Fema | 2005 |
Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Flutamide | 2004 |
Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.
Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Diuretics; Drug Combinations; Drug Therapy, Combin | 2005 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Female; Flutamide; Humans; Insulin Resistance; O | 1995 |
Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients.
Topics: Adolescent; Adult; Contraceptives, Oral; Desogestrel; Dose-Response Relationship, Drug; Drug Therapy | 1994 |
Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androgen Antagonists; Androstenedione; Dehydroepiandrosterone S | 1997 |
Hormonal effects of flutamide in young women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenedione; Estradiol; Female; Flutamide; Follicle Sti | 1998 |
[Finasteride and flutamide in the treatment of hirsutism].
Topics: Administration, Oral; Adult; Androgen Antagonists; Dose-Response Relationship, Drug; Female; Finaste | 1997 |
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Topics: Adult; Bone and Bones; Bone Density; Bone Resorption; Female; Flutamide; Hirsutism; Humans; Polycyst | 1999 |
Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism.
Topics: Adult; Androgen Antagonists; Blood Glucose; C-Peptide; Female; Flutamide; Follicle Stimulating Hormo | 1999 |
Comparison of finasteride versus flutamide in the treatment of hirsutism.
Topics: Adolescent; Adult; Androgen Antagonists; Enzyme Inhibitors; Female; Finasteride; Flutamide; Hirsutis | 1999 |
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.
Topics: Adult; Androgen Antagonists; Double-Blind Method; Female; Finasteride; Flutamide; Hair; Hirsutism; H | 2000 |
A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism.
Topics: Adult; Androgen Antagonists; Body Mass Index; Dehydroepiandrosterone Sulfate; Enzyme Inhibitors; Est | 2000 |
Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Topics: 17-alpha-Hydroxyprogesterone; Activity Cycles; Adult; Androgen Antagonists; Body Mass Index; Dehydro | 2000 |
Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
Topics: Adult; Amenorrhea; Androgen Antagonists; Contraceptives, Oral, Combined; Cyproterone Acetate; Estrad | 2000 |
The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Androgen Antagonists; Arteries; Dehydroepiandrosterone Sulfate; Female; | 2002 |
36 other studies available for flutamide and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Metformin, clomiphene citrate and flutamide effects on oocyte ultrastructure status and quality in PCOS mouse model.
Topics: Animals; Body Weight; Clomiphene; Female; Fertility Agents, Female; Flutamide; Humans; Infertility, | 2022 |
Polycystic ovarian syndrome: a second-take on flutamide.
Topics: Androgen Antagonists; Female; Flutamide; Hirsutism; Humans; Polycystic Ovary Syndrome | 2023 |
[Effects of electroacupuncture on the secretion function of ovarian cells and kisspeptin/kiss1r system in rats with polycystic ovarian syndrome].
Topics: Animals; Electroacupuncture; Female; Flutamide; Humans; Kisspeptins; Luteinizing Hormone; Polycystic | 2023 |
Androgen receptor and uterine histoarchitecture in a PCOS rat model.
Topics: Animals; Animals, Newborn; Aquaporins; Collagen; Dehydroepiandrosterone; Disease Models, Animal; Est | 2020 |
Developmental programming: gestational testosterone excess disrupts LH secretion in the female sheep fetus.
Topics: Animals; Female; Fetal Development; Fetus; Flutamide; Hyperandrogenism; Luteinizing Hormone; Polycys | 2020 |
Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Topics: Adipocytes; Androgen Antagonists; Animals; Aromatase Inhibitors; Body Weight; Disease Models, Animal | 2018 |
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Topics: Androgen Antagonists; Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood G | 2019 |
Endoplasmic Reticulum Stress Activated by Androgen Enhances Apoptosis of Granulosa Cells via Induction of Death Receptor 5 in PCOS.
Topics: Androgen Antagonists; Androgens; Animals; Apoptosis; Endoplasmic Reticulum Stress; Female; Flutamide | 2019 |
Flutamide ameliorates uterine decidualization and angiogenesis in the mouse hyperandrogenemia model during mid-pregnancy.
Topics: Androgen Antagonists; Animals; Decidua; Disease Models, Animal; Embryo Implantation; Female; Flutami | 2019 |
Clinical efficacy of low dose flutamide plus Diane-35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Drug Administration Schedule; Drug Combinations; D | 2013 |
Hirsutism - from diagnosis to use of antiandrogens.
Topics: Androgen Antagonists; Androstenes; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirsutism; H | 2013 |
Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.
Topics: Androgen Antagonists; Androgens; Animals; Estrous Cycle; Female; Fetal Development; Flutamide; Hypog | 2015 |
Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women.
Topics: Adult; Androgen Antagonists; Aromatase; Cell Line; Down-Regulation; Female; Fertilization in Vitro; | 2015 |
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
Topics: Androgen Antagonists; Androgens; Animals; Arteries; Blood Pressure; Body Weight; Dihydrotestosterone | 2015 |
Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.
Topics: Adiposity; Animals; Disease Models, Animal; Embryonic Development; Female; Flutamide; Insulin Resist | 2016 |
Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome.
Topics: Adenylate Kinase; Animals; Cyclin-Dependent Kinase Inhibitor p21; Dihydrotestosterone; Endometrium; | 2015 |
Developmental Programming: Insulin Sensitizer Prevents the GnRH-Stimulated LH Hypersecretion in a Sheep Model of PCOS.
Topics: Androgen Antagonists; Androgens; Animals; Disease Models, Animal; Estrogen Receptor alpha; Female; F | 2016 |
[Low-dose flutamide in the treatment of hyperandrogenism in adolescents].
Topics: Acne Vulgaris; Adolescent; Androgen Antagonists; Body Mass Index; Child; Female; Flutamide; Follow-U | 2008 |
Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome.
Topics: Analgesics, Opioid; Androgen Antagonists; Animals; Cysts; Disease Models, Animal; Dose-Response Rela | 2009 |
[Enhancing effect of androgen receptor antagonist on gonadotropic inductors of ovulation in rats with polycystic ovaries].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Animals; Anovulation; Chorionic Gonadotropin; D | 2009 |
Ovulatory effects of flutamide in the polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Estradiol; Female; Flutamide; Follicle Stimulating Hormone; Humans; Lut | 2013 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome.
Topics: 17-Hydroxysteroid Dehydrogenases; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgen Antag | 2004 |
Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination.
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Androstenedione; Contraceptives, Oral, Hormonal; | 2004 |
Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women.
Topics: Adolescent; Adult; Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Biomarke | 2005 |
Use of antiandrogens as therapy for women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Female; Flutamide; Humans; Hyperandrogenism; Polycystic Ovary Syndrome | 2006 |
Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome.
Topics: Aging; Androgen Antagonists; Body Weight; Child; Drug Therapy, Combination; Female; Fetal Developmen | 2006 |
The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Androstenedione; Area Under Curve; Cohort Studies; Dehydroepiandrostero | 2006 |
Long-term, low-dose flutamide does not cause hepatotoxicity in hyperandrogenic women.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Flutamide; Humans; Hyperandrogenism; Liver; Liver F | 2006 |
Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.
Topics: Adipocytes; Adult; Analysis of Variance; Biological Transport; Cell Differentiation; Cells, Cultured | 2007 |
The use of flutamide in the management of hirsutism.
Topics: Adolescent; Adult; Female; Flutamide; Hirsutism; Hormones; Humans; Polycystic Ovary Syndrome; Sex Ho | 1994 |
Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Flutami | 1995 |
RU486-treated rats show endocrine and morphological responses to therapies analogous to responses of women with polycystic ovary syndrome treated with similar therapies.
Topics: Androgen Antagonists; Animals; Bromocriptine; Disease Models, Animal; Dopamine Agonists; Estrogen An | 1996 |
The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Androstane-3,17-diol; Androstenedione; Cholesterol; Dehydroepiandroster | 1998 |
Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF).
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Adult; Androgen Antagonists; Androgens; A | 1998 |
Treatment of hirsutism in women with flutamide.
Topics: Adult; Analysis of Variance; Androstane-3,17-diol; Androstenedione; Dehydroepiandrosterone; Dehydroe | 1992 |